comparemela.com

Latest Breaking News On - David zaccardelli - Page 5 : comparemela.com

Brokerages Set Verona Pharma plc (NASDAQ:VRNA) PT at $30 00

Shares of Verona Pharma plc (NASDAQ:VRNA – Get Rating) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the […]

Verona Pharma (NASDAQ:VRNA) PT Raised to $32 00

Verona Pharma (NASDAQ:VRNA – Get Rating) had its price objective raised by analysts at Truist Financial from $28.00 to $32.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Truist Financial’s target price points to a potential upside of 51.66% from the stock’s previous close. VRNA has been the topic […]

Amylyx Pharmaceuticals, Inc (NASDAQ:AMLX) Receives Average Recommendation of Moderate Buy from Analysts

Shares of Verona Pharma plc (NASDAQ:VRNA – Get Rating) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued ratings on the stock […]

Verona Pharma plc (NASDAQ:VRNA) Q1 2023 Earnings Call Transcript

Operator: Good morning. Welcome to Verona Pharma s First Quarter 2023 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a mode.

Verona Pharma plc (NASDAQ:VRNA) Short Interest Up 21 8% in April

Verona Pharma plc (NASDAQ:VRNA – Get Rating) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 2,290,000 shares, a growth of 21.8% from the April 15th total of 1,880,000 shares. Based on an average daily volume of 558,400 shares, the short-interest ratio is […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.